Search

Your search keyword '"Clara Dibenedetto"' showing total 9 results
Start Over Author "Clara Dibenedetto"
9 results on '"Clara Dibenedetto"'

1. COVID-19 Vaccine in Lung and Liver Transplant Recipients Exceeds Expectations: An Italian Real-Life Experience on Immunogenicity and Clinical Efficacy of BNT162b2 Vaccine

Author

Letizia Corinna Morlacchi, Gianfranco Alicandro, Sara Uceda Renteria, Nunzio Zignani, Giovanni Giacomel, Valeria Rossetti, Michele Sagasta, Gaia Citterio, Andrea Lombardi, Clara Dibenedetto, Barbara Antonelli, Lorenzo Rosso, Pietro Lampertico, Ferruccio Ceriotti, Francesco Blasi, and Maria Francesca Donato

Subjects
COVID-19 vaccination, solid organ transplant recipient, vaccine immunogenicity, lung transplant recipients, liver transplant recipients, humoral response, Specialties of internal medicine, RC581-951
Abstract

This study assessed humoral and T cell-mediated immune responses to the BNT162b2 vaccine in orthotopic liver transplant (OLT) and lung transplant (LUT) recipients who received three doses of the vaccine from March 2021 at our institution. Serum samples were collected 60 days post-second and third dose to quantify antibodies against the spike region of SARS-CoV-2 while whole blood samples were collected to analyze the SARS-CoV-2-specific T-cell response using an IFN-γ ELISpot assay. We enrolled 244 OLT and 120 LUT recipients. The third dose increased antibody titres in OLT recipients (from a median value of 131 after the second dose to 5523 IU/mL, p < 0.001) and LUT recipients (from 14.8 to 1729 IU/mL, p < 0.001). T-cell response also increased in OLT recipients (from 8.5 to 23 IFN-γ SFU per 250,000 PBMC, p < 0.001) and LUT recipients (from 8 to 15 IFN-γ SFU per 250,000 PBMC, p < 0.001). A total of 128 breakthrough infections were observed: two (0.8%) OLT recipients were hospitalized due to COVID-19 and one died (0.4%); among LUT recipients, seven were hospitalized (5.8%) and two patients died (1.7%). In conclusion, the three-dose schedule of the BNT162b2 vaccine elicited both humoral and T cell-mediated responses in solid organ transplant recipients. The risk of severe COVID-19 post-vaccination was low in this population.

Published
2024
Full Text
View/download PDF

2. Induced myocardial ischemia in candidates to liver transplantation without evidence of heart disease

Author

Luca Mircoli, Niccolò Bacà, Barbara Antonelli, Lucio Caccamo, Emanuele Cattaneo, Federico Colombo, Clara Dibenedetto, Livia Diehl, Maria Francesca Donato, Andrea Faggiano, Massimo Alberto Iavarone, Pietro Lampertico, Cristina Marenghi, Federico Polli, Edoardo Quarenghi, Fabiola B. Sozzi, Cristina Spaziani, Giulia Tosetti, Carlo Valsecchi, Pierluigi Vicardi, Marco Vicenzi, Arianna Zefelippo, Massimiliano Ruscica, and Stefano Carugo

Subjects
Coronary artery disease, computed tomography angiography, end-stage liver disease, Medicine
Abstract

AbstractBackground Coronary artery disease (CAD) is associated with perioperative liver transplantation (LT) mortality. In absence of a defined risk algorithm, we aimed to test whether stress echocardiography and coronary computed tomography angiography (CCTA) could detect CAD in end-stage liver disease (ESLD) patients without previous evidence of heart disease.Methods LT candidates ≥30 years underwent a cardiovascular (CV) assessment through stress echocardiography. CCTA was performed in patients ≥50 years with two or more CV risk factors (e.g. diabetes, CAD family history, dyslipidaemia). Coronary angiography (CAG) was scheduled when stress echocardiography and/or CCTA were positive. Sensibility, specificity, positive and negative predictive values of stress echocardiography and CCTA were assessed by numbers of coronary revascularization (true positives) and lack of acute coronary events over a mean follow-up of 3 years (true negatives).Results Stress echocardiography was performed in 273 patients, CCTA in 34 and CAG in 41. Eight patients had critical coronary lesions, and 19 not-critical lesions. Sensitivity, specificity, positive and negative predictive values were 50.0%, 90.2%, 13.3% and 98.4% for stress echocardiography and 100%, 76.7%, 36.4% and 100% for CCTA. Among 163 patients who underwent LT (57.6%), 16 died and 5 had major adverse CV events over a mean follow-up of 3 years.Conclusions A very low prevalence of CAD in a selected population of ESLD at intermediate to high CV risk was found. A screening based on stress echocardiography and CCTA resulted in low incidence of post-LT acute coronary events in ELSD patients. CAD has no impact on mid-term survival.

Published
2023
Full Text
View/download PDF

3. Hesitancy toward the Full COVID-19 Vaccination among Kidney, Liver and Lung Transplant Recipients in Italy

Author

Andrea Costantino, Letizia Morlacchi, Maria Francesca Donato, Andrea Gramegna, Elisa Farina, Clara Dibenedetto, Mariarosaria Campise, Matteo Redaelli, Marta Perego, Carlo Alfieri, Francesco Blasi, Pietro Lampertico, and Evaldo Favi

Subjects
COVID-19 vaccine, COVID-19, vaccine hesitancy, kidney transplantation, liver transplantation, lung transplantation, Medicine
Abstract

Background: Coronavirus disease 2019 (COVID-19) vaccination hesitancy is a threat as COVID-19 vaccines have reduced both viral transmission and virus-associated mortality rates, particularly in high-risk subgroups. Solid organ transplant recipients (SOTRs) are particularly vulnerable, as the underlying causes of their organ failure and the chronic immunosuppression are associated with a lower immune response to COVID-19 vaccines, and with an excessive risk of death due to SARS-CoV-2 infection. We aimed to evaluate COVID-19 vaccination hesitancy and its reasons in a population of SOTRs. Methods: All the SOTRs attending our post-transplant clinics were asked to fill in a vaccination status form with specific validated questions related to their willingness to receive a third vaccine dose. In the case of negative answers, the patients were encouraged to explain the reasons for their refusal. Among the SOTRs (1899), 1019 were investigated (53.7%). Results: Overall, 5.01% (51/1019) of the SOTRs raised concerns regarding the future third dose vaccination. In more detail, hesitancy rates were 3.3% (15/453), 4.2% (7/166), and 7.3% (29/400) among the investigated liver, lung, and kidney transplant recipients, respectively (p = 0.0018). The main reasons for hesitancy were fear of adverse events (30/51, 58.8%) and perceived lack of efficacy (21/51, 41.2%). Conclusions: Full adherence to ongoing or future vaccination campaigns is crucial to prevent, or at least reduce, COVID-19-related morbidity and mortality in fragile patients. The identification of the reasons influencing COVID-19 vaccination hesitancy in these patients is very important to establish appropriate and targeted patient–doctor communication strategies, and to further implement specific vaccination campaigns.

Published
2022
Full Text
View/download PDF

4. Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study

Author

Arianna Dal Buono, Rossella Meli, Federica Lubrano Lobianco, Nicola Pugliese, Massimo Zuin, Alessio Aghemo, Pier Maria Battezzati, Adriano De Santis, Daniela Maggi, Alessia Giorgini, Clara Dibenedetto, Ana Lleo, Antonio Capogreco, and S. Monico

Subjects
Liver Cirrhosis, Male, medicine.medical_specialty, Genotype, Sustained Virologic Response, Hepacivirus, 030204 cardiovascular system & hematology, elderly, Antiviral Agents, HCV Positive, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Chronic hepatitis, Internal medicine, antiviral therapy, 80 and over, medicine, Humans, Drug Interactions, Pharmacology (medical), tolerability, hepatitis c, Retrospective Studies, Aged, 80 and over, drug interaction, business.industry, Antiviral therapy, food and beverages, General Medicine, Hepatitis C, Chronic, Drug interaction, chronic, aged, Tolerability, 030220 oncology & carcinogenesis, Virologic response, HCV, aged, 80 and over, antiviral agents, cohort studies, drug interactions, female, follow-up studies, genotype, hepacivirus, humans, liver cirrhosis, male, retrospective studies, sustained virologic response, Female, Life study, business, Follow-Up Studies
Abstract

Background: Treatment of chronic Hepatitis C with directly acting antivirals (DAAs) can bring to sustained virologic response (SVR) in approximately 95% of patients. Efficacy and safety of DAAs in ...

Published
2021
Full Text
View/download PDF

5. THU-141-Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients

Author

Alberto Colombo, Sandro Panese, Mauro Viganò, Simona Landonio, Agostino Colli, Barbara Menzaghi, Caterina Uberti-Foppa, Veronica Paon, Paolo Sacchi, Maria Cristina Rossi, Francesca Cattelan, Andrea Capretti, Maria Cristina Vinci, Luisa Pasulo, Valter Vincenzi, S. Lobello, Giada Carolo, Liliana Chemello, Ombretta Spinelli, Roberta D'Ambrosio, Monia Mendeni, Franco Capra, Alessandro Soria, Roberta Soffredini, Maurizio Carrara, M. Colpani, Massimo Puoti, Giancarlo Spinzi, Alfredo Alberti, Pietro Lampertico, Luisa Cavalletto, Angiola Spinetti, Elisabetta Degasperi, Massimo Zuin, Alessio Aghemo, Laura Comi, Giovanna Cardaci, Valentina Zuccaro, Massimo Memoli, Paolo Poggio, Angelo Pan, Vinicio Manfrin, Alessia Giorgini, Marie Graciella Pigozzi, Serena Zaltron, Francesco Castelli, Franco Noventa, Paolo Grossi, Monica Schiavini, Clara Dibenedetto, Antonella d'Arminio Monforte, Roberto Gulminetti, Elisabetta Buscarini, Piergiorgio Scotton, Stefano Fagiuoli, Martina Gambato, Francesco Russo, Andrea Gori, Paolo Fabris, Caterina Pozzan, and Maria Grazia Rumi

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Cohort, medicine, Elbasvir, Grazoprevir, business
Published
2019
Full Text
View/download PDF

6. THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy

Author

Giancarlo Spinzi, Vito Di Marco, Giada Carolo, Caterina Pozzan, Barbara Menzaghi, Giuliana Cologni, Roberta Soffredini, Mauro Viganò, Colombatto Piero, Carlo Magni, Serena Zaltron, Francesco Castelli, Roberta D'Ambrosio, Monia Mendeni, Alfredo Alberti, Paolo Grossi, Massimo Zuin, Maria Grazia Rumi, Veronica Paon, Luisa Pasulo, Alberto Colombo, Pietro Lampertico, Paolo Sacchi, Monica Schiavini, Alessio Aghemo, Andrea Capretti, Maria Cristina Vinci, Valter Vincenzi, Andrea Lombardi, Alessia Giorgini, Lorenzo Difrancesco, Maria Antonietta Di Rosolini, Piergiorgio Scotton, Francesco Russo, Antonio Albanese, Sandro Panese, Andrea Gori, Franco Noventa, Stefano Fagiuoli, F. Cartabellotta, Agostino Colli, Martina Gambato, Caterina Uberti-Foppa, Angelo Pan, Luisa Cavalletto, Clara Dibenedetto, Antonio Di Giacomo, Franco Capra, Angiola Spinetti, S. Lobello, M. Colpani, Ombretta Spinelli, Vinicio Manfrin, Liliana Chemello, Roberto Gulminetti, Alessandro Soria, Irene Cacciola, Maurizia Rossana Brunetto, Vincenza Calvaruso, Antonella d'Arminio Monforte, Massimo Memoli, Elisabetta Buscarini, Alessia Ciancio, and Massimo Puoti

Subjects
medicine.medical_specialty, chemistry.chemical_compound, Hepatology, chemistry, business.industry, Internal medicine, Ribavirin, Genotype, medicine, business, Gastroenterology, Sofosbuvir/velpatasvir
Published
2019
Full Text
View/download PDF

7. Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy

Author

Alessia Ciancio, Angelo Pan, Pietro Lampertico, F. Cartabellotta, Barbara Menzaghi, Alessio Aghemo, S. Lo Bello, Roberta Soffredini, Roberta D'Ambrosio, Monia Mendeni, Roberto Gulminetti, Caterina Pozzan, Piergiorgio Scotton, Mauro Viganò, Sandro Panese, Francesco Russo, Maurizio Carrara, Veronica Paon, Ombretta Spinelli, P. Colombatto, Maurizia Rossana Brunetto, Stefano Fagiuoli, F. Di Lorenzo, Valter Vincenzi, Agostino Colli, Andrea Gori, Martina Gambato, Franco Noventa, Serena Zaltron, Paolo Sacchi, Francesco Castelli, Massimo Zuin, Caterina Uberti-Foppa, Claudio Rossi, Luisa Pasulo, G. Cologni, A. Albanese, V. Di Marco, Andrea Capretti, Maria Cristina Vinci, Giada Carolo, Elisabetta Buscarini, Maria Grazia Rumi, Monica Schiavini, Alessia Giorgini, Alberto Colombo, Andrea Lombardi, P. Del Poggio, Franco Capra, M. Colpani, Liliana Chemello, Carlo Magni, M.A. Di Rosolini, Luisa Cavalletto, Vinicio Manfrin, Alfredo Alberti, A d'Arminio Monforte, A. Digiacomo, Paolo Grossi, Angiola Spinetti, Giancarlo Spinzi, Paolo Fabris, Clara Dibenedetto, Massimo Memoli, Alessandro Soria, Irene Cacciola, Massimo Puoti, Vincenza Calvaruso, and G. Cardaci

Subjects
chemistry.chemical_compound, medicine.medical_specialty, Hepatology, chemistry, business.industry, Ribavirin, Internal medicine, Genotype, Gastroenterology, medicine, business, Sofosbuvir/velpatasvir
Published
2019
Full Text
View/download PDF

8. Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients

Author

Paolo Grossi, Sandro Panese, G. Cardaci, Barbara Menzaghi, Piergiorgio Scotton, Simona Landonio, Agostino Colli, Massimo Zuin, Caterina Uberti-Foppa, Francesco Russo, M. Colpani, Mauro Viganò, Alessia Giorgini, Maria Cristina Rossi, Elisabetta Degasperi, Serena Zaltron, Francesco Castelli, Massimo Memoli, Andrea Gori, Roberta Soffredini, Franco Noventa, S. Lobello, Ombretta Spinelli, Alessandro Soria, A d'Arminio Monforte, Luisa Pasulo, Vinicio Manfrin, Elisabetta Buscarini, Angelo Pan, Monica Schiavini, Maria Grazia Rumi, P. Del Poggio, Alberto Colombo, Valter Vincenzi, Giancarlo Spinzi, Franco Capra, Massimo Puoti, Roberto Gulminetti, Valentina Zuccaro, Stefano Fagiuoli, Alfredo Alberti, Martina Gambato, Luisa Cavalletto, F. Cattelan, Pietro Lampertico, I. Franceschet, Alessio Aghemo, Marie Graciella Pigozzi, L. Comi, Giada Carolo, Liliana Chemello, Veronica Paon, Paolo Sacchi, Andrea Capretti, Maria Cristina Vinci, Roberta D'Ambrosio, Monia Mendeni, Maurizio Carrara, Paolo Fabris, Angiola Spinetti, and Clara Dibenedetto

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Cohort, Gastroenterology, Medicine, Elbasvir, Grazoprevir, business
Published
2019
Full Text
View/download PDF

9. Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II study

Author

Clara Dibenedetto, Caterina Uberti-Foppa, Monica Schiavini, P. Del Poggio, Marie Graciella Pigozzi, Paolo Viganò, M.G. Rumi, Riccardo Centenaro, Luisa Pasulo, Marta Borghi, Barbara Menzaghi, Pietro Lampertico, Andrea Capretti, Maria Cristina Vinci, Alessio Aghemo, Carlo Magni, Elisabetta Buscarini, Massimo Zuin, Angelo Pan, A d'Arminio Monforte, Sergio Lazzaroni, Angiola Spinetti, Omar Giglio, Alessia Giorgini, A. Colli, Lorenzo Morini, M. Colpani, Giancarlo Spinzi, Roberta D'Ambrosio, Alessandro Soria, Alberto Colombo, M. Puoti, Ombretta Spinelli, Andrea Gori, Franco Noventa, Stefano Fagiuoli, F. Maggiolo, and Roberta Soffredini

Subjects
030213 general clinical medicine, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, Hepatology, Chronic hepatitis, business.industry, Internal medicine, medicine, 030211 gastroenterology & hepatology, Glecaprevir / pibrentasvir, business
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results